Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bhatt

Showing results (461-470 of 486) with videos related to

Pageof 49
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanesThomas H Graham, Wensheng Liu, Andreas Verras, et al.
JAMA Ophthalmology|April 24, 2020
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of PrematurityDavid K Wallace, Raymond T Kraker, Sharon F Freedman, et al.
European Urology Oncology|January 31, 2024
Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder CancerParamananthan Mariappan, Allan Johnston, Matthew Trail, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.
JAMA Ophthalmology|April 28, 2017
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing StudyDavid K Wallace, Raymond T Kraker, Sharon F Freedman, et al.
Transplantation and Cellular Therapy|October 16, 2023
Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluationThomas H Graham, Wensheng Liu, Andreas Verras, et al.
JAMA Ophthalmology|March 4, 2021
Overminus Lens Therapy for Children 3 to 10 Years of Age With Intermittent Exotropia: A Randomized Clinical TrialAngela M Chen, S Ayse Erzurum, Danielle L Chandler, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitorsThomas H Graham, Hong C Shen, Wensheng Liu, et al.
Leukemia & Lymphoma|July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemiaMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 49

Showing results (461-470 of 486) with videos related to

Sort By:
Pageof 49
Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanesThomas H Graham, Wensheng Liu, Andreas Verras, et al.
JAMA Ophthalmology|April 24, 2020
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of PrematurityDavid K Wallace, Raymond T Kraker, Sharon F Freedman, et al.
European Urology Oncology|January 31, 2024
Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder CancerParamananthan Mariappan, Allan Johnston, Matthew Trail, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.
JAMA Ophthalmology|April 28, 2017
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing StudyDavid K Wallace, Raymond T Kraker, Sharon F Freedman, et al.
Transplantation and Cellular Therapy|October 16, 2023
Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluationThomas H Graham, Wensheng Liu, Andreas Verras, et al.
JAMA Ophthalmology|March 4, 2021
Overminus Lens Therapy for Children 3 to 10 Years of Age With Intermittent Exotropia: A Randomized Clinical TrialAngela M Chen, S Ayse Erzurum, Danielle L Chandler, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitorsThomas H Graham, Hong C Shen, Wensheng Liu, et al.
Leukemia & Lymphoma|July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemiaMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 49